SCHEMBL4594749

SCHEMBL4594749

COC(=O)CCc1cnc(N)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.55
HRH2 P25021 5/20 0.47
TSHR P16473 2/20 0.46
POLB P06746 2/20 0.44
RPS6KB2 Q9UBS0 1/20 0.43
HTT P42858 2/20 0.41
HSD17B10 Q99714 2/20 0.41
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
RECQL P46063 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
DRD2 P14416 1/20 0.38
HRH1 P35367 1/20 0.38
DRD3 P35462 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
HPGD P15428 1/20 0.38
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL15825194 0.98 SMN1; SMN2 (0.54) SMN1; SMN2HRH2TSHRPOLBRPS6KB2
SCHEMBL16086229 0.91 SMN1; SMN2 (0.52) SMN1; SMN2HRH2TSHRPOLBHTT
SCHEMBL16086477 0.84 SMN1; SMN2 (0.73) SMN1; SMN2HRH2TSHRPOLBHTT
SCHEMBL1636834 0.83 SMN1; SMN2 (0.71) SMN1; SMN2HRH2TSHRPOLBHTT
Hydrochloric Acid SCHEMBL7249126 0.83 SMN1; SMN2 (0.71) SMN1; SMN2HRH2TSHRPOLBHTT
Bromide SCHEMBL15825597 0.83 SMN1; SMN2 (0.71) SMN1; SMN2HRH2TSHRPOLBHTT
SCHEMBL10289763 0.82 RPS6KB2 (0.44) SMN1; SMN2TSHRRPS6KB2HTTHSD17B10
SCHEMBL15825442 0.82 RPS6KB2 (0.44) SMN1; SMN2TSHRRPS6KB2HTTHSD17B10
Bromide SCHEMBL1636830 0.82 SMN1; SMN2 (0.69) SMN1; SMN2HRH2TSHRPOLBHTT
SCHEMBL4008532 0.81 RPS6KB2 (0.43) SMN1; SMN2TSHRRPS6KB2HTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2931734-B1 NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2020-12-02 EP disclosed
EP-2931734-B1 NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2020-12-02 EP disclosed
EP-2931718-B1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME (US) 2019-01-16 EP disclosed
US-9527838-B2 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment MERCK SHARP & DOHME CORP. (US) 2016-12-27 US disclosed
US-9527838-B2 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment MERCK SHARP & DOHME CORP. (US) 2016-12-27 US disclosed
US-9453038-B2 Glucokinase activator compounds, compositions containing such compounds, and methods of treatment MERCK SHARP & DOHME CORP. (US) 2016-09-27 US disclosed
US-9453038-B2 Glucokinase activator compounds, compositions containing such compounds, and methods of treatment MERCK SHARP & DOHME CORP. (US) 2016-09-27 US disclosed
US-9453038-B2 Glucokinase activator compounds, compositions containing such compounds, and methods of treatment MERCK SHARP & DOHME CORP. (US) 2016-09-27 US disclosed
US-20150336991-A1 NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2015-11-26 US disclosed
US-20150336946-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2015-11-26 US disclosed
WO-2014099584-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2014-06-26 WO disclosed
WO-2014099578-A1 NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT MERCK SHARP & DOHME CORP. (US) 2014-06-26 WO disclosed
EP-1948651-A1 THIAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2008-07-30 EP disclosed
US-20070149523-A1 Thiazole Analogues and Uses Thereof 4SC AG (DE) 2007-06-28 US disclosed
WO-2007054357-A1 THIAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2007-05-18 WO disclosed
EP-1785420-A1 Thiazole analogues and uses thereof 4SC AG (DE) 2007-05-16 EP disclosed
US-7037929-B1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2006-05-02 US disclosed
EP-1124810-B9 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA SPA (IT) 2005-12-28 EP disclosed
EP-1124810-B1 2-AMINO-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA SPA (IT) 2005-05-04 EP disclosed
CN-1325389-A 2-aminothiazole derivatives, process for preparing the same and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2001-12-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336946-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT GCK, HK2, GCKR SMN1; SMN2 3803/4885HRH2 1781/4885TSHR 3139/4885
US-20070149523-A1 Thiazole Analogues and Uses Thereof NR3C2, SLC26A4, CLIC4 SMN1; SMN2 2623/4885HRH2 284/4885TSHR 22/4885
US-20150336991-A1 NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT GCK, GCKR, HK2 SMN1; SMN2 3353/4885HRH2 3100/4885TSHR 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.